3D Cell Culture Platforms for Drug Screening

3D cell culture screening has emerged as a pivotal strategy for improving the translational accuracy of preclinical drug testing, addressing a fundamental limitation of conventional two-dimensional (2D) monolayer cultures. Standard 2D systems, while operationally convenient and scalable, impose artificial growth constraints on cells: they alter morphology, disrupt cell–cell and cell–matrix interactions, and fail to reproduce the oxygen and nutrient gradients that characterize solid tissues in vivo. These deficiencies are now widely recognized as significant contributors to the high attrition rate observed in clinical drug development, where more than half of all candidates fail in Phase II and Phase III trials.¹

Three-dimensional (3D) cell culture platforms offer a more biologically faithful alternative by recapitulating the spatial architecture, mechanical properties, and microenvironmental complexity of living tissue. In vitro drug testing using spheroid assays, scaffold-based models, and organoids has demonstrated improved concordance with in vivo pharmacological responses, making physiologically relevant models an increasingly central component of early drug discovery workflows across oncology, toxicology, and beyond.²

From monolayers to 3D: the limitations of conventional cell culture

Cells propagated in 2D monolayer culture on plastic substrates experience a fundamentally unnatural environment. In the absence of a three-dimensional extracellular matrix (ECM), cells spread into flat geometries, lose tissue-specific polarization, and exhibit altered gene expression profiles compared with their in vivo counterparts. Drug penetration in monolayer cultures is unrestricted and uniform, whereas in solid tumors and other tissues, compounds must diffuse across concentration gradients and through compacted cell layers — a physiological reality absent from flat cultures.

The predictive shortfall of 2D models is perhaps most acute in oncology. Tumor cells cultured in monolayer frequently display sensitivities to cytotoxic and targeted agents that are not reproduced when the same compounds are tested in animal models or clinical trials. Three-dimensional culture systems address this discrepancy by recreating the multicellular architecture of solid tumors, including the hypoxic core, proliferating rim, and quiescent intermediate zones that together determine drug distribution and cellular response.³

Spheroid assays: formation methods and screening applications

Multicellular spheroids are the most widely used format for 3D cell culture screening and can be generated by several methods, each with distinct advantages. Ultra-low attachment plates, hanging drop systems, and spinner flask cultures all exploit the tendency of cells to aggregate in the absence of an adhesive substrate. Of these, ultra-low attachment round-bottom plates have gained particular traction in high-throughput screening settings because they produce single, centrally located spheroids of reproducible size that are compatible with automated liquid handling and standard plate-reader detection.⁴

Spheroid assays are routinely applied to the assessment of cytotoxicity, apoptosis induction, spheroid compaction, and drug penetration kinetics. Fluorescence-based endpoints — including live/dead staining, caspase activity, and reactive oxygen species generation — can be quantified using high-content imaging systems adapted for three-dimensional volumes. More complex readouts, such as spheroid invasion into surrounding ECM and resistance to targeted inhibitors, provide information that monolayer assays are structurally incapable of generating. The development of ATP-luminescence viability assays optimized for spheroid volumes has further simplified integration into existing HTS workflows.

Table 1. Overview of 3D cell culture platform types, formation methods, and primary screening applications.

Scaffold-based and hydrogel models for physiologically relevant drug testing

Scaffold-based 3D cultures embed cells within natural or synthetic matrices that mimic ECM composition and mechanical stiffness. Natural polymers such as collagen, fibrin, hyaluronic acid, and basement membrane extract (BME) provide adhesion ligands and growth factor binding sites that support tissue-relevant signaling. Synthetic hydrogels, including polyethylene glycol (PEG)-based formulations, offer tuneable mechanical properties and well-defined chemical environments, facilitating systematic investigation of how matrix stiffness and composition influence drug sensitivity.⁵

Scaffold-based models are particularly valuable for ADME-Tox (absorption, distribution, metabolism, excretion, and toxicity) screening applications, where the goal is to assess compound behavior in organ-relevant tissue architectures. Three-dimensional hepatic models built on collagen or decellularized ECM scaffolds demonstrate improved retention of cytochrome P450 enzyme activity relative to hepatocyte monolayers, extending the window over which metabolic competence can be evaluated. Similarly, 3D cardiac and renal microtissues embedded in hydrogel matrices are being deployed for safety pharmacology assessments that were previously impossible at the in vitro stage.⁶

Organoids as patient-derived platforms for precision drug screening

Organoids represent the most biologically complex class of 3D culture platform currently available for in vitro drug testing. Derived from adult stem cells, induced pluripotent stem cells, or primary tumor tissue, organoids self-assemble into three-dimensional structures that recapitulate the cellular hierarchy, tissue architecture, and molecular signatures of the organ of origin. Patient-derived cancer organoids (also referred to as tumoroids) have demonstrated the ability to preserve tumor genetic heterogeneity, resistance mechanisms, and pharmacotypic profiles across serial passage, making them well-suited to personalized drug screening.³

The predictive validity of patient-derived organoids has been evaluated in several prospective clinical studies, with organoid drug sensitivity data showing statistically significant correlations with patient treatment outcomes in colorectal, pancreatic, and gastric cancers. Biobanks of well-characterized patient-derived organoids spanning multiple tumor types have been established and are increasingly accessible to academic and industrial researchers, providing representative disease models for mechanistic studies and first-in-class drug evaluation.⁷

Key application domains for organoid-based in vitro drug testing include:

• Personalized oncology: matching patients to active treatment regimens based on ex vivo drug sensitivity profiles
• Co-clinical trial design: using patient-derived models to guide real-time treatment selection alongside clinical trial enrollment
• Target validation: confirming gene–drug response relationships in physiologically relevant cell systems
• Toxicity screening: assessing organ-specific safety liabilities in hepatic, cardiac, renal, and intestinal organoids
• Resistance mechanism profiling: characterizing acquired drug resistance in serially passaged tumor organoids

Challenges in implementing 3D cell culture screening at scale

Despite their clear advantages, 3D cell culture platforms present significant operational and technical challenges that have slowed their routine adoption in high-throughput drug discovery. Spheroid formation is sensitive to seeding density, media composition, and plate surface chemistry, and achieving consistent size and morphology across a plate presents difficulties not encountered with monolayer cultures. Variability in spheroid size directly affects drug penetration depth, endpoint readout intensity, and dose–response curve shape, introducing a source of assay noise absent from conventional 2D formats.⁸

Improving Oral Bioavailability Prediction With Human Models

Join this webinar to explore how an integrated human gut/liver microphysiological system (MPS), combined with mechanistic modeling, provides deeper insight into oral drug disposition.
View Webinar

Advertisement

Organoid culture introduces additional complexity. Basement membrane extract preparations, the most commonly used scaffold for organoid growth, are derived from murine tumor tissue and exhibit batch-to-batch variation in composition and growth factor content that can confound reproducibility. The transition to fully defined synthetic matrices is technically demanding and has not yet been standardized for most organoid lineages. Cost per data point in organoid-based screening remains substantially higher than for monolayer or spheroid assays, limiting current applications to smaller compound sets and hit validation rather than primary library screens.

Analytical infrastructure also requires adaptation. High-content imaging systems must be configured for volumetric z-stack acquisition to faithfully capture 3D structures, and image analysis pipelines require algorithms capable of segmenting and quantifying complex three-dimensional morphologies. These requirements increase capital investment and data processing demands relative to standard 2D HTS workflows.

Outlook for 3D cell culture platforms in drug discovery

The trajectory of 3D cell culture screening points toward progressive integration into mainstream preclinical drug discovery pipelines, driven by continued improvements in organoid standardization, scaffold chemistry, and high-content analytical tools. The development of defined, animal-free matrices that support organoid growth with reduced batch variability will be a critical enabler of routine high-throughput organoid screening. Simultaneously, advances in microfluidic organ-on-a-chip technologies are beginning to incorporate 3D cell culture elements into perfused, multi-organ systems capable of capturing systemic pharmacokinetic interactions.

Regulatory acceptance of 3D physiologically relevant models as part of the preclinical submission package is advancing in parallel with scientific validation. As evidence accumulates demonstrating that 3D in vitro drug testing data improve the predictive value of preclinical safety and efficacy assessments, the use of these platforms is expected to expand across therapeutic areas including immuno-oncology, fibrosis, neurodegeneration, and cardiovascular disease. The integration of patient-derived 3D models with multi-omics profiling and artificial intelligence-driven drug response prediction represents a convergence that could meaningfully reduce the cost and timeline of bringing new medicines to patients.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.